Marchés français ouverture 3 h 13 min

Global CNS Therapeutics Industry

ReportLinker FR

The global market for CNS Therapeutics is projected to reach US$137. 7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders.

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CNS Therapeutics Industry" - https://www.reportlinker.com/p01139068/?utm_source=GNW
Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer’s, Parkinson’s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase. Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe. The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years.
- Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson’s, Alzheimer’s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer’s drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators. Better understanding of the electrochemical processes of the brain and development of disease-modifying therapies is driving growth in the antiepileptic drugs market. Combination CNS Therapies are especially gaining prominence for their ability to target multiple pathologic processes simultaneously. Volume of CNS prescriptions for chronic pain and psychiatric disorders will grow in the coming years as the burden of mental illnesses intensifies as a result of lifestyle and societal changes and physiological stress. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications. A key trend in the market is pharma companies’ efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.
- Competitors identified in this market include, among others, Alkermes Plc., Allergan Plc., AstraZeneca Plc., Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals Inc., Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc.,Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A.


Read the full report: https://www.reportlinker.com/p01139068/?utm_source=GNW

CNS THERAPEUTICS MCP-1
MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2
CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Central Nervous System (CNS) Therapeutics: A Prelude
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2019
List of FDA Approved CNS Drugs: 2018
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Global Market Overview
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
New Approvals (2019 and 2018)
Disease Overview
Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA’s New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy: 2016-2019
Review of Anti-Epilepsy Drugs
Vimpat®
Keppra®
Lamictal
Tegretol®
Sabril®
Perampanel
Zonegran®
Topamax®
Trileptal®
Neurontin®
Lyrica®
Depakine®
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Ongoing Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica’s Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies: As of October 2019
Migraine Ongoing Phase III Studies: As of October 2019
Select Pain Management Drugs
Flupirtine
Lyrica®
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly’s Emgality Receives FDA Approval
Anti-Alzheimer's
Market Overview
Global Alzheimer's Prevalence by Age Group
Alzheimer's Phase III Completed Studies
Alzheimer’s Phase III Ongoing Studies
Treatment for Alzheimer’s
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer’s Drugs
Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
The Clinical Trials for Aducanumab
Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer’s Market
Alzheimer’s Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
PR
Alzheimers Disease
Updated FDA Standards Make Way for Increased Alzheimer’s Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer’s to Dampen Market Growth
Elenbecestat’s Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer’s Association Provides Grant to Longeveron
BPN14770 Demonstrates Potential to Protect Against Alzheimer`s Symptoms
A Review of Select Anti-Alzheimer’s Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer ’s disease
Alzheimer’s Effect on Brain
Causes for Alzheimer’s
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Anti-Parkinson's
Market Overview
Select Top Selling Drugs for Parkinson's Disease
Nourianz, An Add-on Medication for Treating Episodes of Parkinson’s Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson’s Disease
NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s disease
Parkinson’s Phase III Completed Studies: As of October 2019
Parkinson's Ongoing Phase III Studies: As of October 2019
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
FDA Announces Imminent Discontinuation of Certain Formulations of GSK’s Requip for PD and RSL Treatment
A Review of the Parkinson’s Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Select Top Selling Anti-Depressants in 2018
Select Antidepressant Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Recent Approvals of Anti-Depressants
Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Sales of Vyvanse in 2018
Pipeline Drugs in Phase III for ADHD: As of October 2019
Select ADHD Drugs
Vyvanse
Concerta
Adderall
A Review of Attention Deficit Hyperactivity Disorder (ADHD)
Consequences of ADHD
What Leads to ADHD?
Insomnia
Overview
List of Approved Drugs for Insomnia
Pipeline Drugs for Insomnia: As of October 2019
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia

2. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Alkermes Plc. (Ireland)
Allergan Plc. (Ireland)
AstraZeneca Plc. (UK)
BIAL Group (Portugal)
Bristol-Myers Squibb (USA)
Eisai Co., Ltd. (Japan)
Endo Pharmaceuticals Inc. (USA)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Purdue Pharma L.P. (USA)
Sanofi (France)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB S.A., (Belgium)

3. MARKET TRENDS & DRIVERS
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
Growing Middle Class Population in Emerging Regions to Spur the Market
Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
Growing Penetration of Generic Drugs Emerges as a Key Trait
Global Spending on Generic Drugs Vis-à-vis Branded Drugs (2019): Percentage Share Breakdown of Dollar Spending by Drug Category
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE
Table 1: CNS Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
Table 2: CNS Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
Table 3: CNS Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: Pain Management (Segment) World Market by Region/Country in US$ Million: 2018 to 2025
Table 5: Pain Management (Segment) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
Table 6: Pain Management (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
Table 7: Anti-Psychotics (Segment) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
Table 8: Anti-Psychotics (Segment) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
Table 9: Anti-Psychotics (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
Table 10: Anti-Depressants (Segment) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
Table 11: Anti-Depressants (Segment) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
Table 12: Anti-Depressants (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
Table 13: Anti-Epilepsy (Segment) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
Table 14: Anti-Epilepsy (Segment) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
Table 15: Anti-Epilepsy (Segment) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Anti-Alzheimer's (Segment) World Market by Region/Country in US$ Million: 2018 to 2025
Table 17: Anti-Alzheimer's (Segment) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Anti-Alzheimer's (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
Table 19: Anti-Parkinson's (Segment) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
Table 20: Anti-Parkinson's (Segment) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
Table 21: Anti-Parkinson's (Segment) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
Table 22: Other Segments (Segment) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
Table 23: Other Segments (Segment) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
Table 24: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Aging Population: A Strong Demographic Driver
North American Elderly Population by Age Group (1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer’s Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
Popular Antipsychotic Drugs in the US
The US Anti-Psychotic Drugs Market by Indication (2019E): Percentage Share Breakdown of Value Sales
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
The US ADHD Drugs Market by Drug Category (2019E): Market Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants
The US ADHD Drugs Market by Type (2019E): Market Share Breakdown of Total Prescription Sales for Branded & Generic Drugs Groups
Adult ADHD Drugs Continue to Widen their Share
The US ADHD Drugs Market by Drug Category (2019E): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups
Market Analytics
Table 25: United States CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
Table 26: CNS Therapeutics Market in the United States by Segment: A Historic Review in US$ Million for 2009-2017
Table 27: United States CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
CANADA
CNS Diseases: Facts & Figures
Market Analytics
Table 28: Canadian CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
Table 29: Canadian CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
Table 30: CNS Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
JAPAN
Table 31: Japanese Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
Table 32: CNS Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
Table 33: Japanese CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
CHINA
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
Market Analytics
Table 34: Chinese CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
Table 35: CNS Therapeutics Historic Market Analysis in China in US$ Million by Segment: 2009-2017
Table 36: Chinese CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Ageing Population Boosts Demand
65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
Market Analytics
Table 37: European CNS Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025
Table 38: CNS Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
Table 39: European CNS Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
Table 40: European CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
Table 41: CNS Therapeutics Market in Europe in US$ Million by Segment: A Historic Review for the Period 2009-2017
Table 42: European CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
FRANCE
Table 43: CNS Therapeutics Market in France by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
Table 44: French CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
Table 45: French CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
GERMANY
Table 46: CNS Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 47: German CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 48: German CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
ITALY
Market Snapshots
Market Analytics
Table 49: Italian CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
Table 50: CNS Therapeutics Historic Market Analysis in Italy in US$ Million by Segment: 2009-2017
Table 51: Italian CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
NICE Recommendations on CNS Therapeutics
Market Analytics
Table 52: United Kingdom Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
Table 53: CNS Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
Table 54: United Kingdom CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
SPAIN
Table 55: Spanish CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
Table 56: Spanish CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
Table 57: CNS Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
RUSSIA
Table 58: Russian CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
Table 59: CNS Therapeutics Market in Russia by Segment: A Historic Review in US$ Million for 2009-2017
Table 60: Russian CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 61: Rest of Europe CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
Table 62: CNS Therapeutics Market in Rest of Europe in US$ Million by Segment: A Historic Review for the Period 2009-2017
Table 63: Rest of Europe CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
ASIA-PACIFIC
India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia
Market Analytics
Table 64: Asia-Pacific CNS Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
Table 65: CNS Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
Table 66: Asia-Pacific CNS Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 67: CNS Therapeutics Market in Asia-Pacific by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
Table 68: Asia-Pacific CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
Table 69: Asia-Pacific CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
AUSTRALIA
Table 70: CNS Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 71: Australian CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 72: Australian CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
INDIA
Table 73: Indian CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
Table 74: Indian CNS Therapeutics Historic Market Review by Segment in US$ Million: 2009-2017
Table 75: CNS Therapeutics Market in India: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
SOUTH KOREA
Table 76: CNS Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 77: South Korean CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 78: CNS Therapeutics Market Share Distribution in South Korea by Segment: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
Table 79: Rest of Asia-Pacific Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
Table 80: CNS Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
Table 81: Rest of Asia-Pacific CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 82: Latin American CNS Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025
Table 83: CNS Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
Table 84: Latin American CNS Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
Table 85: Latin American CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
Table 86: CNS Therapeutics Historic Market Analysis in Latin America in US$ Million by Segment: 2009-2017
Table 87: Latin American CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
ARGENTINA
Table 88: Argentinean CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
Table 89: CNS Therapeutics Market in Argentina in US$ Million by Segment: A Historic Review for the Period 2009-2017
Table 90: Argentinean CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
BRAZIL
Table 91: CNS Therapeutics Market in Brazil by Segment: Estimates and Projections in US$ Million for the Period 2018-2025
Table 92: Brazilian CNS Therapeutics Historic Market Scenario in US$ Million by Segment: 2009-2017
Table 93: Brazilian CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
MEXICO
Table 94: CNS Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 95: Mexican CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 96: Mexican CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 97: Rest of Latin America CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
Table 98: CNS Therapeutics Market in Rest of Latin America by Segment: A Historic Review in US$ Million for 2009-2017
Table 99: Rest of Latin America CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
MIDDLE EAST
Table 100: The Middle East CNS Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
Table 101: CNS Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017
Table 102: The Middle East CNS Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025
Table 103: The Middle East CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018 to 2025
Table 104: The Middle East CNS Therapeutics Historic Market by Segment in US$ Million: 2009-2017
Table 105: CNS Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
IRAN
Table 106: Iranian Market for CNS Therapeutics: Annual Sales Estimates and Projections in US$ Million by Segment for the Period 2018-2025
Table 107: CNS Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Segment for the Period 2009-2017
Table 108: Iranian CNS Therapeutics Market Share Analysis by Segment: 2009 VS 2019 VS 2025
ISRAEL
Table 109: Israeli CNS Therapeutics Market Estimates and Forecasts in US$ Million by Segment: 2018-2025
Table 110: CNS Therapeutics Market in Israel in US$ Million by Segment: A Historic Review for the Period 2009-2017
Table 111: Israeli CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 112: Saudi Arabian CNS Therapeutics Market Growth Prospects in US$ Million by Segment for the Period 2018-2025
Table 113: CNS Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Segment: 2009-2017
Table 114: Saudi Arabian CNS Therapeutics Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED ARAB EMIRATES
Table 115: CNS Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 116: United Arab Emirates CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 117: CNS Therapeutics Market Share Distribution in United Arab Emirates by Segment: 2009 VS 2019 VS 2025
REST OF MIDDLE EAST
Table 118: CNS Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Segment for the Period 2018-2025
Table 119: Rest of Middle East CNS Therapeutics Historic Market Analysis in US$ Million by Segment: 2009-2017
Table 120: Rest of Middle East CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
AFRICA
Table 121: African CNS Therapeutics Market Estimates and Projections in US$ Million by Segment: 2018 to 2025
Table 122: CNS Therapeutics Market in Africa by Segment: A Historic Review in US$ Million for 2009-2017
Table 123: African CNS Therapeutics Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 157 (including Divisions/Subsidiaries - 181)
Read the full report: https://www.reportlinker.com/p01139068/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001